DIAGENIC PARTNERS WITH DNAVision TO OFFER FIRST BREAST CANCER AND ALZHEIMER’S GENE-EXPRESSION BLOOD TESTS

10/28/2008 6:00 AM EST

OSLO. – November 28 2008 –DiaGenic ASA (OSL:DIAG) today announced that it has signed a service provider agreement with DNAVision, a leading panEuropean provider of gene expression-based diagnostic testing and services. With this laboratory service and following CE marking scheduled in early 2009, DiaGenic will be able to offer healthcare providers and patients in Europe its innovative blood-based gene-expression test for early detection of breast cancer and for Alzheimer’s disease in a CLIA/ISO17025 certified environment.

Joint press release from DNAVision and DiaGenic is enclosed.

Contact:

MD PhD Erik Christensen, CEO
Telephone: +47 95939918
e-mail:

DiaGenic ASA

RSS

DiaGenic ASA is an innovative Norwegian life sciences company founded in 1998 and listed on the Oslo Stock Exchange.

DiaGenic develops patient-friendly tests for the early diagnosis of devastating diseases where early in...

CONTACT

DiaGenic ASA
+(47) 2324 8950
http://www.diagenic.com

Recent Releases

DiaGenic reports high 85% accuracy for blood based diagnosis in early Parkinson patients in European multicenter study
2/8/2012 11:28 AM EST
Presentation of results for fourth quarter 2011
2/7/2012 4:11 AM EST
Financial calendar for 2012
12/12/2011 10:20 AM EST
Presentation at DNB Markets Nordic Health Care Conference 2011
12/6/2011 3:30 AM EST
DiaGenic presents promising findings in pilot study
11/3/2011 11:00 AM EST

DIAGENIC PARTNERS WITH DNAVision TO OFFER FIRST BREAST CANCER AND ALZHEIMER’S GENE-EXPRESSION BLOOD TESTS

DiaGenic ASA

Related documents

Recent Releases